The Conversation (0)
Kalytera Therapeutics announces major management changes and an expansion of their leadership team.
Kalytera Therapeutics (TSXV:KALY; OTCQB:KALTF) announces major management changes and an expansion of their leadership team.
As quoted in the press release:
Andrew L. Salzman, M.D., who previously served as Kalytera’s Chief Executive Officer and Chief Medical Officer, and as a member of Kalytera’s Board of Directors, will be leaving the Company, effective June 21, 2017. Robert Farrell, J.D., President and CFO of Kalytera, will assume the role of interim Chief Executive Officer (“CEO”). Concurrent with Mr. Farrell’s appointment as interim CEO, the Company has expanded its senior management team with three new appointments.
Joining Mr. Farrell as members of Kalytera’s leadership are David Bassa, Chief Operating Officer, Moshe Yeshurun, M.D., Chief Medical Officer, and Sari Prutchi-Sagiv, Ph.D., Chief Scientific Officer, each of whom previously held senior management positions at Talent Biotechs.
Click here to read the full press release.
Source: globenewswire.com
